Conference Coverage
Conference Coverage
High-dose MTX-based chemo is well tolerated in older PCNSL patients
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central...
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
Complementary medicine use common among patients on TKIs
GLASGOW – A survey of chronic myeloid leukemia patients taking tyrosine kinase inhibitors (TKIs) revealed that more than one-third were taking...
Conference Coverage
Model inspired by Netflix, Amazon may help guide MDS treatment
NEWPORT BEACH, CALIF. – The researchers used an algorithm to help predict response or resistance to lenalidomide with a high degree of accuracy....
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
Osimertinib again shows strength in NSCLC with leptomeningeal metastases
GENEVA – The overall response rate was 55% for patients with NSCLC and leptomeningeal metastases receiving...
Conference Coverage
Sorafenib plus GCLAM held safe in AML, MDS phase-1 study
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.
Video
Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors
PHILADELPHIA – This past year has been a tough one for ARBs.
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.